Moderna Inc. has announced positive results from a Phase 3 efficacy study of its seasonal influenza vaccine candidate, mRNA-1010. The study, which compared mRNA-1010 to a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older, demonstrated a superior relative vaccine efficacy of 26.6% in the overall study population. The vaccine candidate showed strong efficacy against various influenza strains, including A/H1N1, A/H3N2, and the B/Victoria lineages. Safety and tolerability were consistent with previous studies, with most adverse reactions being mild and no significant differences observed in the rates of adverse events between groups. Moderna plans to present these findings at an upcoming medical conference and will engage with regulators on filing submissions for mRNA-1010.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.